These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22232754)

  • 1. Characterizing the impact of renal impairment on the clinical pharmacology of biologics.
    Meibohm B; Zhou H
    J Clin Pharmacol; 2012 Jan; 52(1 Suppl):54S-62S. PubMed ID: 22232754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs.
    Czock D; Keller F; Seidling HM
    Br J Clin Pharmacol; 2012 Jul; 74(1):66-74. PubMed ID: 22242561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
    Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
    J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient impact of automated glomerular filtration rate reporting on drug dosing for hospitalized older adults with concealed renal insufficiency.
    Kalender-Rich JL; Mahnken JD; Wetmore JB; Rigler SK
    Am J Geriatr Pharmacother; 2011 Oct; 9(5):320-7. PubMed ID: 21920825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of dalbavancin in patients with renal or hepatic impairment.
    Marbury T; Dowell JA; Seltzer E; Buckwalter M
    J Clin Pharmacol; 2009 Apr; 49(4):465-76. PubMed ID: 19318696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safe drug prescribing for patients with renal failure].
    Tanaka A; Shimizu H; Matsuo S
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():58-66. PubMed ID: 18074518
    [No Abstract]   [Full Text] [Related]  

  • 8. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
    Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
    Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease.
    Zhang L; Xu N; Xiao S; Arya V; Zhao P; Lesko LJ; Huang SM
    J Clin Pharmacol; 2012 Jan; 52(1 Suppl):79S-90S. PubMed ID: 22232757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of oxaliplatin: a critical review.
    Graham MA; Lockwood GF; Greenslade D; Brienza S; Bayssas M; Gamelin E
    Clin Cancer Res; 2000 Apr; 6(4):1205-18. PubMed ID: 10778943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of tumor size on renal function and prediction of renal insufficiency after radical nephrectomy in patients with renal cell carcinoma.
    Ohno Y; Nakashima J; Ohori M; Hashimoto T; Iseki R; Hatano T; Tachibana M
    J Urol; 2011 Oct; 186(4):1242-6. PubMed ID: 21849191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment.
    Lalonde RL; Wagner JA
    Clin Pharmacol Ther; 2009 Nov; 86(5):557-61. PubMed ID: 19776736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine.
    Malhotra B; Gandelman K; Sachse R; Wood N
    J Clin Pharmacol; 2009 Apr; 49(4):477-82. PubMed ID: 19246724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight heparins in patients with renal insufficiency.
    Symes J
    CANNT J; 2008; 18(2):55-61. PubMed ID: 18669012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment and prevention of osteoporosis in patients with decreased renal function].
    Vestergaard P; Eiken PA
    Ugeskr Laeger; 2008 Jan; 170(4):227-30. PubMed ID: 18282452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of anakinra in subjects with different levels of renal function.
    Yang BB; Baughman S; Sullivan JT
    Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
    Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
    Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NTP Toxicology and Carcinogenesis Studies of Tetrafluoroethylene (CAS No. 116-14-3) in F344 Rats and B6C3F1 Mice (Inhalation Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1997 Apr; 450():1-321. PubMed ID: 12594525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
    Dimopoulos MA; Terpos E; Chanan-Khan A; Leung N; Ludwig H; Jagannath S; Niesvizky R; Giralt S; Fermand JP; Bladé J; Comenzo RL; Sezer O; Palumbo A; Harousseau JL; Richardson PG; Barlogie B; Anderson KC; Sonneveld P; Tosi P; Cavo M; Rajkumar SV; Durie BG; San Miguel J
    J Clin Oncol; 2010 Nov; 28(33):4976-84. PubMed ID: 20956629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.